Kundu Sourav 4

What Happened Sourav Kundu, Senior Vice President of Development & Manufacturing at NextCure (NXTC), was granted 8,270 derivative shares on January 30, 2026. The reported acquisition price is $0.00 per share, indicating a stock-based award (e.g., restricted stock units or similar) rather than a cash purchase or sale.

Key Details

• Transaction date: January 30, 2026; Filing date: February 3, 2026 (filed within the required 2 business days).
• Amount: 8,270 derivative shares granted; reported price $0.00 per share.
• Vesting (footnote): 25% vests on January 30, 2027; the remaining 75% vests in 36 monthly installments beginning February 28, 2027.
• Shares owned after transaction: Not specified in the filing.
• Filing code: "A" (award/grant). No 10b5-1 plan, tax withholding, or late-filing indication noted in the filing.

Context This is a compensation-related award subject to multi-year vesting, intended to retain and incentivize the executive rather than an immediate market transaction. Such awards are common and do not by themselves signal a buy or sell decision; unlike outright purchases, they reflect company compensation policy and long-term alignment with shareholders.